A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors
Status:
Recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
This is a Phase 1/2a, first-in-human, open-label study of JAB-8263, this study has two parts:
solid tumor dose escalation and expansion study and hematology tumor dose escalation and
expansion study.
These two parts will determine the maximum tolerated dose (MTD), recommended Phase 2 dose
(RP2D) and assess the DLT of JAB-8263 in treatment with patients with advanced solid tumors
and hematology tumors separately. 30 subjects each will be enrolled.